pembrolizumab,binimetinib,encorafenib
ono pharmacueticals,pierre fabre,pfizer,merck
['binimetinib', 'starboard', 'melanoma', 'encorafenib', 'pembro']
#aacr23 | section 46
ct069 - randomized phase 3 study (starboard) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic braf v600-mutant melanoma
ryan j. sullivan, md
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.